Allurion Technologies (NYSE:ALUR – Get Free Report) was downgraded by equities researchers at Chardan Capital from a “buy” rating to a “neutral” rating in a research note issued to investors on Thursday, Marketbeat.com reports.
A number of other equities research analysts have also recently issued reports on ALUR. Roth Capital raised shares of Allurion Technologies to a “strong-buy” rating in a research note on Friday, September 6th. Roth Mkm started coverage on shares of Allurion Technologies in a research note on Friday, September 6th. They set a “buy” rating and a $2.00 target price on the stock. Finally, TD Cowen started coverage on shares of Allurion Technologies in a research note on Wednesday, October 2nd. They set a “buy” rating and a $2.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $2.88.
Get Our Latest Stock Report on ALUR
Allurion Technologies Price Performance
Allurion Technologies (NYSE:ALUR – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $11.77 million during the quarter. Analysts anticipate that Allurion Technologies will post -0.4 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Allurion Technologies stock. CVI Holdings LLC purchased a new position in shares of Allurion Technologies Inc. (NYSE:ALUR – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 521,440 shares of the company’s stock, valued at approximately $520,000. Allurion Technologies accounts for about 0.5% of CVI Holdings LLC’s portfolio, making the stock its 28th largest holding. CVI Holdings LLC owned 1.09% of Allurion Technologies as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 21.39% of the company’s stock.
About Allurion Technologies
Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
Read More
- Five stocks we like better than Allurion Technologies
- How to Calculate Options Profits
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Top Biotech Stocks: Exploring Innovation Opportunities
- Top-Performing Non-Leveraged ETFs This Year
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Allurion Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allurion Technologies and related companies with MarketBeat.com's FREE daily email newsletter.